glp-1 agonist eli lilly Abu Dhabi, United Arab Emirates – and Company (NYSE: LLY) today reported positive topline results from its Phase 3 ATTAIN-2 trial of orforglipron, an investigational oral receptor agonist, in Eli Lilly's $1 Trillion Boom:
Pay in 4 interest-free payments of $5.77 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17



























